{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071992","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.693086+00:00","generated_at":"2026-05-21T05:27:26.971245+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025","bullets":["Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.","Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.","R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.","On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.","Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071992","json":"https://secwatch.observer/filing/0000950170-25-071992.json","markdown":"https://secwatch.observer/filing/0000950170-25-071992.md","text":"https://secwatch.observer/filing/0000950170-25-071992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/0000950170-25-071992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/pyxs-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:27:26.971245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}